Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy
Latest Information Update: 16 Aug 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Enzalutamide
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-199
- Sponsors Merck Sharp & Dohme Corp.
- 20 Dec 2022 This trial has been completed in Spain and Italy (Date of the global end of the trial : 28-Feb-2022), according to European Clinical Trials Database record.
- 02 Apr 2022 This trial has been completed in Finland and Italy (Date of the global end of the trial : 28-Feb-2022), according to European Clinical Trials Database record.
- 06 Mar 2022 Status changed from active, no longer recruiting to completed.